Trial Profile

TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary) ; Azathioprine; Ciclosporin; Methotrexate; Mycophenolic acid
Indications Atopic dermatitis
Focus Adverse reactions; Therapeutic Use
Acronyms TREAT NL

Most Recent Events

01 Sep 2021 Results (n=93) from subset of TREAT NL registry; assessing work ability and quality of working life in atopic dermatitis patients treated with dupilumab, published in the Journal of Dermatology
11 Jun 2020 New trial record
30 May 2020 Results (N=221), assessing effectiveness and safety of up to 84 weeks of dupilumab treatment, published in the Journal of the American Academy of Dermatology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com